skip to main content
UK Health Security Agency

PEO1-CDDP

PEO1-CDDP

Catalogue No.

16012001

Cell Line Name

PEO1-CDDP

Cell Line Description

The PEO1-CDDP cell line was established by in vitro exposure of the PEO1 line to cisplatin commencing at 25 nMol/L cisplatin and increasing to one µMol/L over a period of four months. The resistant cell line thus obtained was then passaged in the absence of cisplatin for a further four months to ensure that the resistance remained stable. PEO1-CDDP is from the same patient as the PEO1, PEO4 and PEO6 cell lines (ECACC Catalogue numbers 10032308, 10032309 and 10032310). The PEO1-CDDP cell line is an in vitro model to understand the changes in EGF signalling after the onset of cisplatin resistance.

General Info

Species

Human

Unique to ECACC

Yes

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

erbB receptors, oestrogen receptor

Tissue of Origin

Ovary

Morphology

Polygonal epithelia

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10,12
D3S1358: 16
D5S818: 11,12
D7S820: 10
D8S1179: 13
D13S317: 10
D16S539: 9
D18S51: 16,17
D21S11: 32.2
FGA: 20
Penta D: 14
Penta E: 11,12
TH01: 9.3
TPOX: 9,11
vWA: 15, 16

Karyotype

For modal chromosome numbers see Langdon SP et al (1988) Cancer Research Nov 1; 48(21):6166-72.

Applications

The PEO1-CDDP Cell Line is an in vitro model to understand the changes in EGF signalling after the onset of cisplatin resistance. Coupled with this change in drug sensitivity, this model also has a modified responsiveness to ligands of the erbB receptor family. This model will be helpful in studying the changes in cellular signalling after drug treatment, which are currently attracting a great deal of interest and this model will be of particular relevance when cytotoxic therapy is combined with signalling inhibitors.

Disease

Cystadenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells/cm² using 0.05% trypsin/EDTA solution. Cells are cultured at 37°C, in 95% air and 5% CO₂, and passaged every 3 to 4 days

Culture Medium

RPMI 1640 containing 10% heat-inactivated FCS. Cells are maintained routinely at 37°C in a humidified atmosphere of 5% CO₂/95% air. Supplement medium with Cisplatin (CDDP) at 1 µM/L.

Growth Mode

Adherent

Additional Info

Depositor

Ximbio (formerly known as Cancer Research Technologies Limited)

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Macleod et al (2005) Cancer Research Aug 1; 65:6789-6800. PMID: 16061661 Mullen et al (1996) Int. J Cancer. 67(6):816-20. PMID: 8824553

Bibliography

Langdon SP et al (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Research Nov 1; 48(21):6166-72. PMID: 3167863. Langdon SP et al (1990) Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer Aug; 62(2):213-6. PMID: 2386737. Langdon SP et al (1988) Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines. Cancer Research Nov 1; 48(21):6161-5. PMID: 3167862.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: PEO1-CDDP (ECACC 16012001).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.